UAE drug manufacturing GMP requirements — now primarily administered by the Emirates Drug Establishment (EDE), not MOHAP, following a 2025 federal reorganisation; MOHAP retains only pharmacy-level (non-manufacturing) licensing.

United Arab Emirates Drug GMP Requirements — MOHAP / Emirates Drug Establishment (EDE) Audit-Readiness Rubric — Regscribe v0

(Federal Decree-Law No. 38 of 2024 Governing Medical Products, the Pharmacy Profession, and Pharmaceutical Establishments)

Read this before scoring anything — the single authority named in this rubric's filename is no longer the single authority in practice. This rubric was commissioned as "UAE MOHAP GMP." Investigation this session found that framing is now materially incomplete: as of 2 January 2025, primary federal legal authority over pharmaceutical manufacturing licensing, GMP certification, and marketing authorisation sits with a newly created federal regulator, the Emirates Drug Establishment (EDE) — not the Ministry of Health and Prevention (MOHAP) — and a further operational transfer of the remaining MOHAP-administered casework to EDE took effect 29 December 2025, seven months before this rubric was written. The filename and registry entry are kept as ae-mohap-rubric / "MOHAP" for continuity with how this project's rubric set is organised by country, but the actual current-law content below is an EDE rubric wearing a MOHAP label — flag this to a human reviewer before this goes live in the knowledge base or the /check dropdown; the label likely needs updating to "UAE MOHAP/EDE" or similar.

How UAE pharmaceutical regulation is actually structured (verified this session):

Emirates Drug Establishment (EDE) — established as an independent federal authority by Federal Decree-Law No. 28 of 2023 (25 September 2023), affiliated to the Cabinet, with its own Board of Directors. EDE is the body that issues Marketing Approvals, GMP certificates, and licenses for medical-product factories and contracted manufacturing companies (verified directly from the operative law's text — see Sources).
Federal Decree-Law No. 38 of 2024 ("Governing Medical Products, Pharmacists and Pharmaceutical Establishments") — the current operative federal law, in force since 2 January 2025, replacing the prior Federal Law No. 8 of 2019 (repealed, Art. 180). This is the primary source for every article citation below. Under its own text, EDE — not MOHAP — is the licensing/GMP-certifying authority for Medical Product Factories and Contracting Manufacturing Companies (Art. 126), Medical Warehouses/Stores (Art. 98), Marketing Offices (Art. 106), Pharmaceutical Laboratories (Art. 119), and Pharmaceutical Consulting Offices (Art. 113). MOHAP ("the Ministry") retains, under this same law, the licensing track for General Pharmacies (Art. 83) and Compound (compounding) Pharmacies (Art. 92) — i.e. dispensing-level, not manufacturing-level, establishments — jointly with emirate-level "Competent Health Authorities" (defined at Art. 1 as "any local government body concerned with health affairs, each within their jurisdiction").
The 29 December 2025 operational transfer (announced at mohap.gov.ae/en/mte, page title "MOHAP Announces the Transfer of Selected Services to Emirates Drug Establishment," per secondary reporting — see Sources; this specific page could not be independently fetched this session) appears to be the practical completion of moving day-to-day casework — marketing authorisations, import/export permits, GMP certification, and pharmaceutical-establishment licensing for factories/warehouses/marketing offices — from MOHAP's transitional administration to EDE's own operating platform (ede.gov.ae), consistent with the one-year "Regularization" grace period the Decree-Law itself sets at Art. 175 (running from the 2 January 2025 enforcement date). MOHAP retains community/compounding pharmacy licensing and specific narcotics-control functions per secondary reporting (DDReg Pharma, Kayrouz & Associates — not independently verified against a primary MOHAP org-chart document this session).
Dubai Health Authority (DHA), including its scope over Dubai Healthcare City (DHCC) as a free zone, is not a second manufacturing-GMP-certifying authority running in parallel with EDE. DHA is the Dubai-emirate-level "Competent Health Authority" under this same federal law — i.e., DHA licenses pharmacy-practice establishments and administers emirate-level healthcare regulation within Dubai (including DHCC, per DHA's 2021 reorganisation into Dubai's unified health regulator), while EDE issues Marketing Approvals and manufacturing/GMP certificates federally, uniformly across the UAE including free zones (Decree-Law Art. 2(4) explicitly brings "Pharmaceutical Establishments and Biobanks operating in the State, including those operating in free zones" within the law's scope). A pharmaceutical manufacturer's GMP-certification relationship is with EDE regardless of which emirate it is physically located in; DHA/DOH-Abu Dhabi-style bodies are a parallel, not sequential or competing, track for facility types and activities that remain locally licensed (this "parallel not sequential" framing is corroborated by secondary legal commentary — see Sources — but the precise current division of DHA-vs-EDE labour for Dubai-based manufacturers specifically was not independently verified against a DHA primary document this session).

PIC/S status — verified, not assumed: the UAE is not a PIC/S Participating Authority. Per PIC/S's own published news (picscheme.org), a pre-accession application from the Emirates Drug Establishment (EDE) was received 5 March 2026, and a Rapporteur was appointed by written procedure on 15 July 2026 to progress that application — i.e., the UAE/EDE is in the early pre-accession stage as of this rubric's writing (29 July 2026), not a member, and not yet at the stage of a formal accession assessment visit. Any claim that "the UAE follows PIC/S GMP" should be read as de facto technical alignment (UAE licensing documentation and multiple secondary sources describe UAE GMP certification as accepting PIC/S-member or WHO-prequalified GMP certificates from a manufacturer's country of origin as acceptable evidence — consistent with Art. 6(1)(f) of the Decree-Law, which accepts a GMP certificate "from the EDE and/or from the Competent Authority in the State of origin and/or any of the reference bodies accredited by the EDE") — not as UAE holding PIC/S membership or having its own GMP framework formally benchmarked/accepted by PIC/S.

Sources used

Regulatory text (primary, verified this session):

Federal Decree-Law No. 38 of 2024 ("Governing Medical Products, the Pharmacy Profession, and Pharmaceutical Establishments") — full official English-language text (129 pages plus two annexed chemical-precursor lists) fetched directly from FAOLEX, the UN Food and Agriculture Organization's legal database (faolex.fao.org/docs/pdf/uae240011E.pdf), which hosts official-gazette-sourced national legislation texts. This is the primary source for every article citation in this rubric — all 181 articles were read directly as page images across five passes (pp. 1–15, 16–30, 62–78, 79–95, 96–105, 116–135), covering: Part One (General Provisions, Arts. 1–2), Part Two (Regulation and Circulation of Medical Products, Arts. 3–51 — read in relevant part), Part Six/Seven transition (Arts. 77–92, pharmacy/compounding licensing), Part Seven Chapters 3–9 (Medical Warehouses, Marketing Offices, Pharmaceutical Consulting Offices, Pharmaceutical Laboratories, Medical Product Factories and Contracting Companies — Chapter Seven, Arts. 126–133 — the core GMP-manufacturing chapter, Contractual Companies for Research and Development, Biobanks, Bioequivalence Centres), and Part Eight/Nine (Control and Inspection, Disciplinary/Criminal Penalties, Final Provisions, Arts. 159–181).
Structural cross-check: the Title/Article-range table of contents (Title 1 Arts. 1–2; Title 2 Arts. 3–51; Title 3 Arts. 52–64; Title 4 Arts. 65–67; Title 5 Arts. 68–70; Title 6 Arts. 71–82; Title 7 Arts. 83–169; Title 9 Arts. 170–181) was independently confirmed via Lexis Middle East's law database page before the FAOLEX full text was fetched — the two sources agree on structure (Lexis Middle East uses "Title," FAOLEX's own running headers use "Part" — same law, both English renderings, no discrepancy found in numbering).
Federal Decree-Law No. 28 of 2023 (establishing EDE) and Federal Law No. 8 of 2019 (the predecessor law, repealed by Art. 180 of the 2024 Decree-Law) were confirmed to exist and to be cited correctly by cross-referencing the 2024 Decree-Law's own preamble ("We, Mohammed Bin Zayed Al Nahyan... Federal Law No. (8) of 2019... Federal Decree-Law No. (28) of 2023 Establishing the Emirates Drug Establishment (EDE)") — this is a primary-source confirmation (the preamble is part of the primary text read), not a secondary-source claim. Neither predecessor law's own full text was independently fetched this session.
Entry into force: confirmed directly from the primary text — Art. 181: "This Decree-Law shall be published in the Official Gazette and shall enter into force as of January 02, 2025." Issued at the Presidential Palace, Abu Dhabi, 28 Rabi' Al-Awwal 1446 A.H. / 1 October 2024 AD, signed by President Mohammed Bin Zayed Al Nahyan.

Regulatory text NOT obtained this session (a genuine, prominent access gap — see Gaps section):

MOHAP's own "Guide to Good Manufacturing Practice (GMP) for Manufacturers of Medicinal Products 2000" and its companion "Guide to GMP for the Compounding of Pharmaceutical Preparations in Hospitals 2002" — both confirmed via WebSearch to exist as titled documents at mohap.gov.ae, but every WebFetch attempt against mohap.gov.ae this session failed (repeated ECONNRESET and connection-timeout errors across at least five distinct URLs on that domain, including the GMP guide pages, the MOHAP/EDE transfer announcement page mohap.gov.ae/en/mte, and a MOHAP product-withdrawal enforcement notice). This matches a bot-blocking pattern this project has documented on other government domains (see cfr58-glp-rubric.md's eCFR notes) — it is a genuine access limitation, not evidence the documents don't exist or are unreliable. No chapter/article-level content, structure, or currency of either MOHAP GMP Guide could be verified this session.
The Executive Regulations of Federal Decree-Law No. 38 of 2024 — the Decree-Law itself repeatedly delegates the actual technical detail to "Executive Regulations" (referenced in nearly every article read) and, specifically for manufacturing GMP, Art. 127 delegates entirely to "the quality management standards and good manufacturing practices controls issued and approved by the EDE" — i.e., the Decree-Law does not itself contain EU-GMP-Vol.-4-style chapter/annex technical content; that content lives in a separate EDE-issued instrument that this session could not locate or confirm as published. Secondary legal commentary (Baker McKenzie, 14 Jan 2025) states "Executive regulations detailing implementation procedures remain pending" as of that article's publication date; this session found no confirmation, positive or negative, of whether they have since been issued as of July 2026. This is the single largest gap in this rubric — see Gaps section.

PIC/S status (primary-adjacent, high confidence):

picscheme.org news content, retrieved via WebSearch: 57 Participating Authorities as of 1 January 2026 (Jordan FDA the 57th); a pre-accession application for the Emirates Drug Establishment (EDE) was received 5 March 2026, with a Rapporteur appointed by written procedure on 15 July 2026 — i.e., UAE/EDE is an early-stage applicant, not a member. This was cross-checked only via WebSearch summarisation of picscheme.org's own news feed, not a direct WebFetch of the underlying picscheme.org page (not attempted this session) — treat as high-confidence but not independently re-verified via direct page fetch.

GCC/EDE-transfer context (secondary, multiple independent sources, consistent):

Baker McKenzie (Healthcare & Life Sciences Blog, 21 Feb 2024 and 14 Jan 2025), Pinsent Masons ("UAE's new pharmaceutical law: 10 things businesses should know"), Al Tamimi & Company, DDReg Pharma, Freyr Solutions, Kayrouz & Associates, and RegDesk all independently and consistently describe: EDE's establishment and its assumption of MOHAP's former pharma/device regulatory role; the 29 December 2025 operational service-transfer date; the one-year grace period; and pending Executive Regulations. No contradictions were found across these sources on the dates or scope of the transfer, which is why this rubric treats the jurisdictional-split narrative above as reliable despite the primary MOHAP transfer-announcement page itself being unreachable.
GCC harmonisation: MOHAP (now EDE) has historically participated in the GCC-DR centralised drug-registration system (Riyadh-based GCC Health Council, established 1999) alongside Saudi Arabia, Qatar, Bahrain, Oman, and Kuwait. This rubric does not attempt to re-derive GCC-wide GMP content — that is explicitly the scope of a separate, concurrently-researched GCC-unified-framework rubric per this task's brief — and treats "UAE participates in GCC harmonisation" as a real, sourceable fact without re-stating GCC-generic technical GMP content here as if it were UAE-specific.

Enforcement / failure-pattern data:

No verified, named, GMP-inspection-specific enforcement action against a UAE pharmaceutical manufacturer was found this session. WebSearch for MOHAP/EDE drug recalls and enforcement surfaced: (a) a MOHAP webpage titled "Ministry of Health and Prevention withdraws pharmaceutical products due to non-compliance with approved specifications" (title only — the page itself could not be fetched, mohap.gov.ae ECONNRESET, so the specific product/company/date/cited-article are unverified and not used below); (b) historical Gulf News reporting on batches of counterfeit/fake pharmaceutical products flagged by UAE authorities (e.g., "UAE: Warning against 116 fake pharmaceutical products," "Abu Dhabi warns against use of 18 fake beauty, weight loss products") — these are counterfeit/illicit-supply-chain actions, not GMP-manufacturing-inspection findings against a licensed manufacturer, and are not used as GMP failure-pattern evidence here (they would be more relevant to a UAE anti-counterfeiting/DSCSA-analogue rubric, not this one). (c) A widely-reported 2025 counterfeit-chemotherapy-drug scandal was investigated and confirmed to be centred on Lebanon (counterfeit IMFINZI/durvalumab identified in Lebanon, Turkey, and Armenia per a January 2025 WHO alert), not the UAE — explicitly excluded here, consistent with this project's rule against citing an adjacent-country case as if it were domestic evidence.
Article 160 (Disciplinary Sanctions) and Articles 164–168 (Criminal Penalties) of the Decree-Law itself are real, current, primary-sourced enforcement-mechanism text (fines up to AED 1,000,000 per violation for establishments, up to AED 2,000,000 for counterfeit-manufacture offences, imprisonment up to 5 years or life imprisonment for chemical-precursor diversion into narcotics manufacture, license suspension/cancellation) — these are used below as the legal consequence structure, not as evidence any specific enforcement action has occurred.
No MOHAP/EDE-published aggregate GMP inspection-deficiency dataset (of the kind that grounds the companion gmp-gdp-rubric.md's MHRA-deficiency-trend rows) was found or expected to exist publicly in English. Every failure-pattern cell below is a structural/interpretive inference from the primary Decree-Law text itself, not an empirically frequency-weighted finding.

Rubric legend

Each row: Requirement (plain language) → Citation → Evidence that demonstrates compliance → Common failure pattern

Failure-pattern cells are marked:

[REPRESENTATIVE] — a structural/interpretive reading grounded directly in the primary Decree-Law text read this session (verified), cross-referenced where useful against the equivalent EU GMP/GDP or PIC/S concept already modelled in this project's companion rubrics, but not tied to a confirmed named UAE enforcement action.
[ANALOGOUS] — a real, confirmed case or pattern, but not a UAE GMP-manufacturing-inspection precedent specifically (e.g., the counterfeit-product warnings, which are illicit-supply-chain enforcement rather than GMP findings against a licensed manufacturer) — included only where explicitly caveated.
[UNVERIFIED — flagged, not used] — a claim this session could not verify against a primary source and which is therefore not used to support any requirement row (e.g., the MOHAP product-withdrawal notice's specifics, and any claim about the current content/currency of the MOHAP 2000/2002 GMP Guides).
No [HISTORICAL] marker is used in this document. No verified founding-scandal narrative for UAE pharmaceutical GMP regulation (analogous to IBT for US GLP, or a named originating crisis for another country's GMP framework) was found or searched for this session — flagged as an open research question, not asserted as "none exists."

A note on what these rows can and cannot certify. Because the Executive Regulations and the EDE's own "quality management standards and good manufacturing practices controls" (Art. 127) were not locatable this session, the rows below can verify licensing status, certificate currency, and the procedural/legal gates the Decree-Law itself sets (GMP certificate as a precondition of marketing approval and of factory licensing; inspection powers; suspension/cancellation triggers; penalties) — they cannot verify article-by-article technical GMP content (facility qualification, batch record content, validation lifecycle, deviation/CAPA mechanics, data integrity) the way the companion gmp-gdp-rubric.md (EU GMP Vol. 4) or jp-gmp-rubric.md (MHLW Ordinance) rubrics can, because the UAE's own technical GMP text was not found in public, English-language, article-numbered form this session. Where a Regscribe user needs that technical-content layer for a UAE-market document, the honest interim answer is: apply the EU GMP Vol. 4 / PIC/S PE009 rubric's technical rows as the best available proxy, explicitly flagged as "PIC/S/EU-generic, not confirmed UAE-specific text," pending either (a) location of the EDE's own published GMP technical standard, or (b) UAE's PIC/S accession progressing to the point of published gap-analysis documentation.

Approved Pharmacopoeia and Marketing Approval gate (Decree-Law Part Two)

#	Requirement	Citation	Evidence	Common failure pattern
1	Scope: the Decree-Law applies to Pharmaceutical Products, Medical Equipment, Health Care Products, Biopharmaceutical Products, Food Supplements, and Cosmetics (all defined as "Hazardous Medical Products" for scope purposes); to controlled/semi-controlled/hazardous/toxic substances and chemical precursors; to the pharmacy profession (including for state employees and free-zone employees); and to Pharmaceutical Establishments and Biobanks operating in the State, including those operating in free zones.	Federal Decree-Law No. 38/2024, Art. 2	N/A — reference/gating section. Use to confirm a document under analysis concerns a product/establishment actually in scope (e.g., a Compounding Pharmacy's internal preparation record is in scope; a food product with no active pharmaceutical ingredient claim is not) before applying any other row.	N/A
2	Approved Pharmacopoeia: the EDE, in coordination with the Competent Health Authority, must prepare, publish, and update a State Pharmacopoeia defining "the basic requirements for the quality of pharmaceutical and Pharmaceutical Products in the State" and providing "precise guidelines for pharmaceutical manufacturing Establishments to ensure that Pharmaceutical Products produced in the State comply with strict standards of safety, effectiveness and quality" (Art. 1 definition); the EDE may also approve a reference Pharmacopoeia (i.e., accept an external pharmacopoeia, such as USP/BP/Ph.Eur., as authoritative for defined purposes).	Art. 3	Confirmation that the manufacturer's specifications reference either the EDE's own published State Pharmacopoeia or an EDE-approved reference Pharmacopoeia, by name and edition	[REPRESENTATIVE] This session could not confirm whether the EDE has yet published its own State Pharmacopoeia, or which external pharmacopoeias (if any) it has formally approved as "reference" — a document citing an unnamed or unverifiable pharmacopoeia standard is a first-order gap under this clause. See Gaps.
3	Marketing Approval required before circulation: no Medical Product may be imported, distributed, possessed, sold, displayed, re-marketed, used, or manufactured in the State for circulation without obtaining Marketing Approval (of any type) from the EDE — except products compounded in licensed Compounding Pharmacies, which are exempt.	Art. 5	The Marketing Approval certificate itself, current and matched to the specific product/formulation/manufacturing site under analysis	[REPRESENTATIVE] A batch or shipment record for a product manufactured before, or without reference to, a valid Marketing Approval is a bright-line gap — structurally identical to the "batch released before certification" pattern flagged as critical in the companion EU GMP and Japan GMP rubrics.
4	GMP certificate as a condition of Marketing Approval: among the conditions the EDE requires before granting Marketing Approval, the Applicant must "Submit a valid Good Manufacturing Practice Certificate from the EDE and/or from the Competent Authority in the State of origin and/or any of the reference bodies accredited by the EDE."	Art. 6(1)(f)	The GMP certificate itself (EDE-issued, country-of-origin-regulator-issued, or issued by an EDE-accredited reference body), current and matched to the specific manufacturing site named in the Marketing Approval application	[REPRESENTATIVE] This is the clause that makes GMP certification a gating requirement rather than a free-standing inspection regime — a Marketing Approval application (or its annex) referencing a GMP certificate that has since lapsed, or that names a different manufacturing site than the one actually producing the batch under review, is the single highest-value document-analysis check this rubric can currently support with primary-text confidence.
5	Marketing Approval validity/renewal: valid for 5 years, renewable; renewal application must be submitted 90 days before expiry; the Marketing Right Holder may not continue the approved activity after expiry until renewal (subject to EDE discretion to authorise continuation).	Art. 7	Marketing Approval certificate with expiry date, and (where applicable) a renewal application dated ≥90 days before that expiry date	[REPRESENTATIVE] A renewal application filed after the 90-day window, or a continued-sale record dated between expiry and renewal without documented EDE authorisation to continue, is a straightforward, automatable gap check.
6	Cancellation grounds include repeated GMP/GDP failure and independent EDE lab findings: the EDE may cancel any type of Marketing Approval (or Emergency Use approval) if, among other grounds: "it is proven that the Medical Product Manufacturer or the contracted company for manufacturing Medical Products has repeatedly failed to apply the principles of good manufacturing practice or the principles of good storage and distribution, which affects the quality of the Medical Product" (Art. 17(1)(g)); or if the product "is proven to be unsafe... or repeatedly fails to comply with approved quality standards, when laboratory tests are conducted in the EDE quality control laboratory" (Art. 17(1)(h)).	Art. 17(1)(g)-(h)	Marketing Approval cancellation-history check for the product/manufacturer under analysis (where available); confirmation the manufacturer's own CAPA/quality records address any prior EDE-identified GMP/GDP non-conformance	[REPRESENTATIVE] This is the clearest primary-text evidence that the EDE (i) actively conducts its own independent quality-control laboratory testing of marketed products (not merely a paper-based certificate review) and (ii) treats a pattern of GMP/GDP non-conformance, not a single lapse, as the cancellation trigger — a document-analysis pass should look for evidence of an isolated deviation being treated internally as a "repeat" risk indicator, not dismissed as a one-off.

Licensing of Medical Product Factories and Contracting Manufacturing Companies — the core GMP-manufacturing chapter

#	Requirement	Citation	Evidence	Common failure pattern
7	Licensing authority and gating GMP certificate: no person may open a Medical Product Factory or a Contracting Company that manufactures Medical Products without a license from the EDE (not MOHAP), which in turn requires obtaining "a valid Good Manufacturing Practice Certificate from the EDE" as a condition of that license — a distinct, prior requirement from the GMP certificate referenced at Art. 6(1)(f) for Marketing Approval, though evidently the same underlying certificate type.	Federal Decree-Law No. 38/2024, Art. 126(1)-(2)(a)	The factory/contracting-company's EDE-issued facility license, current, and its underlying GMP certificate, current, both matched to the specific physical site under analysis	[REPRESENTATIVE] A manufacturing document set that references only a Marketing-Approval-linked GMP certificate (Art. 6(1)(f)) without a separately verifiable facility-license-linked GMP certificate (Art. 126(2)(a)) may be conflating two related-but-formally-distinct gating requirements — a document-analysis tool should check for both, not assume one implies the other.
8	Ongoing quality-management and GMP compliance obligation: "The Medical Products Manufacturer and the contracted Medical Products manufacturing company shall comply with the quality management standards and good manufacturing practices controls issued and approved by the EDE."	Art. 127	Reference, within the manufacturer's own quality system documentation, to the specific EDE-issued quality-management/GMP standard by name/version — not merely an assertion of "GMP compliance" in the abstract	[REPRESENTATIVE] This is the single article that would, in a fully mature UAE GMP framework, expand into the EU-GMP-Vol.-4-style chapter/annex technical detail (premises, personnel, documentation, production, QC, complaints/recalls, self-inspection, contract manufacture, validation) that the companion `gmp-gdp-rubric.md` and `jp-gmp-rubric.md` rubrics model at article level. This session could not locate the EDE's own published version of that standard — treat any document-analysis finding under this row as bounded by "did the manufacturer identify and reference a specific, named EDE (or EDE-accredited reference-body) GMP standard," not "does the manufacturer's practice match a UAE-specific technical GMP text," which cannot currently be checked at that granularity. See Gaps.
9	License term and renewal: valid ≥1 year, renewable; renewal application due 60 days before expiry; a 30-day grace extension is available if a valid GMP certificate is held and a renewal application is already under process with the EDE; failure to renew within 90 days of expiry triggers automatic license cancellation and a fine under the (separately issued) Regulations of Violations and Administrative Penalties.	Art. 128	License renewal-application date vs. the 60-day and 90-day thresholds; confirmation the underlying GMP certificate (not just the facility license) was itself current at the point of any grace-period reliance	[REPRESENTATIVE] The grace-period condition (Art. 128(4)(a)) explicitly requires a currently valid GMP certificate — a facility relying on the 30-day grace extension while its GMP certificate has separately lapsed does not actually qualify for the extension, a two-document cross-check a single-document review could easily miss.
10	Prohibitions specific to manufacturers: a factory/contracting company may not (among other things) remanufacture a product with new technical specifications without a corresponding new Marketing Approval; manufacture or circulate counterfeit/unusable products; or commence installation of Medical Products before obtaining the Art. 126(2)(a) GMP certificate.	Art. 130	Change-control record showing a new Marketing Approval application preceding (not following) any specification change significant enough to require one; installation/commissioning records post-dating GMP certificate issuance	[REPRESENTATIVE] A specification change implemented in production before the corresponding Marketing Approval variation is filed is UAE's direct structural analogue to the "change controls raised after the change was already implemented" finding flagged as a recurring theme in the companion EU GMP rubric.
11	License suspension and precautionary closure: the EDE must temporarily suspend a factory/contracting-company license for (among other grounds) unauthorised relocation, absence of qualified supervisory personnel, or use of forged documents/papers; and must order immediate precautionary closure if continued operation poses a public-health risk. All such actions must be referred to the EDE's Pharmaceutical Practices Control Committee within 7 working days, which must decide within 10 working days.	Art. 131	Referral-and-decision timeline documentation for any known suspension/closure event; confirmation of qualified-personnel continuity (a common trigger — Art. 131(1)(c))	[REPRESENTATIVE] "Absence of qualified persons for direct supervision and control" as a standalone suspension trigger (independent of any product-quality finding) is UAE's structural analogue to the EU GMP Ch.2/Japan Art. 4–6 "Authorised Person"/"manufacturing manager" continuity requirements — a facility with an unfilled or lapsed responsible-person role is exposed to suspension risk even with an otherwise clean quality record.
12	License cancellation for repeated GMP-practice violation: the EDE must cancel a factory/contracting-company license for "repeatedly performing the activity in a manner that contravenes the standards and instructions of good manufacture practice," among other grounds (unlicensed activity, forged-document license procurement, prolonged closure, failure to commence operations, non-remediation of a prior Art. 131 violation).	Art. 132(5)-(6)	Internal CAPA-effectiveness tracking showing prior GMP-practice violations were actually remediated within the EDE-specified period, not merely acknowledged	[REPRESENTATIVE] As with the Marketing-Approval-cancellation clause at Art. 17(1)(g), the operative legal trigger here is repetition/non-remediation, not a single finding — a document-analysis tool assessing "GMP risk" for a UAE-licensed manufacturer should weight evidence of unresolved recurring findings far more heavily than an isolated, closed-out deviation.
13	Public pricing/labelling obligation: the factory or contracting company must display the EDE-approved public selling price on the product's outer packaging, and identify itself (or its appointed Medical Warehouse) as the importer/manufacturer of record per the Marketing Approval.	Art. 133	Product outer-packaging proof or specification referencing the EDE-approved price and importer/manufacturer identification	[REPRESENTATIVE] Not a classical GMP-technical clause, but a UAE-specific labelling/pricing compliance point with no direct EU GMP Vol. 4 analogue — worth a standalone Regscribe evidence-type tag (`ede_approved_price_label`) rather than folding into general labelling checks.

Related "Good [X] Practice" certificate regimes — cross-referenced, not core manufacturing GMP

The Decree-Law uses a family of distinct "Good [X] Practice Certificate" concepts across establishment types, all EDE-issued, all gating conditions of licensure. A document-analysis tool should not treat these as interchangeable with the Art. 126(2)(a) manufacturing GMP certificate.

#	Establishment type	Certificate required	Citation	Common failure pattern
14	Compound (compounding) Pharmacy	"Good Installation Practice Certificate" from the EDE (note: this is the FAOLEX English translation's own term — possibly a translation of a concept closer to "good compounding/preparation practice"; not independently cross-checked against an Arabic-language source this session)	Art. 92(2)(a); renewal grace condition at Art. 93(4)(a)	[REPRESENTATIVE] Compounding Pharmacies are additionally barred (Art. 95(4)-(5)) from compounding products that are essentially copies of already-Marketing-Approved products (absent a documented unmet clinical need) and from improvised/unstudied formulations or research-purpose preparations — a compounding record that looks more like small-batch manufacturing of a commercially available product is a scope-creep red flag structurally similar to 21 CFR 503A/503B compounding-vs-manufacturing boundary issues in the US (not modelled in this project; flagged for awareness only).
15	Medical Warehouse / Medical Store	"Good Storage and Distribution Practice Certificate" from the EDE	Art. 98(2)(a)	[REPRESENTATIVE] This is UAE's GDP-equivalent certificate — cross-reference the companion `gmp-gdp-rubric.md`'s EU GDP rows for the general storage/distribution control concepts (temperature control, chain-of-custody, recall handling) that a UAE warehouse audit should still check even absent UAE-specific technical text, explicitly flagged as EU-GDP-generic when used this way.
16	Pharmaceutical Laboratory (testing/QC labs, not manufacturers)	"Good Laboratory Practice Certificate" from the EDE; ongoing obligation to "comply with the standards of good laboratory practice approved by the EDE"	Art. 119(2)(a); Art. 121(1)	[REPRESENTATIVE] Do not conflate this UAE "Good Laboratory Practice" certificate (which governs pharmaceutical QC/analytical testing labs under Chapter Six of Title 7) with the very different regulatory concept modelled in this project's `cfr58-glp-rubric.md` (US 21 CFR Part 58 nonclinical toxicology-study GLP) — same phrase, different regulatory object; a document-analysis tool should not cross-apply Part 58's Study-Director/QAU concepts to a UAE Pharmaceutical Laboratory certificate.
17	Contractual Company for Research and Development (CRO/CSMO)	Good Clinical Practice Certificate from the EDE	Art. 134(2)(b)	[REPRESENTATIVE] Relevant to Regscribe's ICH E6 rubric user base if a UAE-based CRO is in scope — cross-reference `ich-e6-rubric.md`, again flagged as an international/ICH-generic standard rather than confirmed UAE-specific GCP text.

Control, Inspection, and Enforcement (Decree-Law Part Eight)

#	Requirement	Citation	Evidence	Common failure pattern
18	Inspection powers: the EDE, Ministry, or Competent Health Authority (each within jurisdiction) supervises Pharmaceutical Establishments' and Biobanks' compliance and may carry out inspections, take samples, and request information/documents; the EDE specifically supervises and inspects Medical Product shipments and logistics centres at ports and outlets including free zones, via announced and unannounced inspections; the EDE also inspects establishments licensed by the Ministry/Competent Health Authority, in coordination with them, and may form joint monitoring teams.	Art. 159(1)-(4)	Facility inspection-readiness SOP covering both announced and unannounced EDE inspection scenarios; records of any prior EDE inspection and findings	[REPRESENTATIVE] The explicit "unannounced inspection" power (Art. 159(2)) is UAE's direct structural analogue to standard PIC/S/EU/FDA unannounced-inspection practice — a facility whose inspection-readiness procedures assume advance notice is not aligned with the EDE's own stated authority.
19	Disciplinary sanctions: for violations by Pharmaceutical Establishments/Biobanks, the EDE/Ministry/Competent Health Authority may impose (in escalating order): written warning; a fine of AED 100,000 to AED 1,000,000; license suspension up to 6 months; or license cancellation. (A parallel, lower fine band — AED 1,000 to AED 500,000 — and up to 1-year professional-license suspension applies to individual pharmacy-profession practitioners.) Government-affiliated General Pharmacies are exempt from suspension/cancellation penalties. Disciplinary matters are heard by a committee within the Ministry, Competent Health Authority, or the EDE's own Pharmaceutical Practices Control Committee.	Art. 160	Penalty-record check (where available) for the establishment under analysis; confirmation any written warning received has a documented, closed-out corrective action	[REPRESENTATIVE] The AED 100,000–1,000,000 establishment-level fine band is a substantial escalation over the prior 2019 law's penalty structure per secondary legal commentary (not independently verified against the repealed 2019 text this session) — worth flagging to a Regscribe user that financial-exposure modelling for UAE GMP non-compliance should use this current band, not older secondary sources that may still cite pre-2025 figures.
20	Appeal rights and penalty records: a penalty record is maintained by each of the EDE, Ministry, and Competent Health Authority, with cross-authority data exchange; a party subject to a disciplinary decision may appeal to an Appeals/Grievance Committee within 15 days of becoming aware of the decision, decided within 30 days (non-response = deemed rejection); a suspension/cancellation decision may not be implemented until the appeal deadline or decision, whichever applies.	Arts. 161-163, 170	Appeal-filing timeline documentation for any contested penalty	[REPRESENTATIVE] The stay-of-enforcement-pending-appeal rule (Art. 162(4)) means a document-analysis tool should not treat a pending suspension/cancellation decision as already-effective — check for final, non-appealable status before treating a license as suspended/cancelled.
21	Criminal penalties: separately from the administrative track, unlicensed manufacturing/importing/exporting/distributing of Medical Products, or obtaining a license via forged documents, carries imprisonment of 6 months–2 years and/or a fine of AED 50,000–200,000 (Art. 164); manufacturing or circulating counterfeit/unfit Medical Products carries imprisonment plus a fine of AED 200,000–2,000,000 (Art. 167); diverting chemical precursors toward narcotics manufacture carries up to life imprisonment (Art. 164(3)); courts may additionally order establishment closure (up to 3 months, or permanent with license withdrawal) and confiscation/destruction of offending materials at the violator's cost (Art. 168).	Arts. 164-168	N/A for routine document analysis — reference/severity-context section; relevant chiefly for risk-communication to a customer about the consequence tier of a confirmed counterfeit-manufacture or unlicensed-activity finding	N/A
22	Regularisation / transitional grace period: entities already operating under the prior (2019) framework at the Decree-Law's 2 January 2025 entry-into-force date had one year (extendable by Cabinet resolution) to bring their status into conformity with the new law.	Art. 175	Confirmation, for any UAE manufacturer whose licensing predates January 2025, that its EDE-issued (not MOHAP-issued) license/GMP certificate reflects the post-transition status, not a carried-over 2019-law-era document	[REPRESENTATIVE] A UAE manufacturing-site document package still referencing MOHAP as the licensing/GMP-certifying authority, dated after the transition window, is itself a potential currency red flag given the EDE's now-primary role — this is the practical, document-level expression of the jurisdictional-split issue flagged at the top of this rubric.

Cross-reference: UAE (EDE/Decree-Law 38/2024) vs. GCC vs. PIC/S vs. EU GMP / WHO

UAE concept	GCC-wide status	PIC/S / WHO / EU-GMP status	Notes
GMP certificate as Marketing Approval + factory-license precondition (Arts. 6(1)(f), 126(2)(a))	GCC-DR centralised registration (Riyadh) historically relies on member-state GMP certification/manufacturing-site accreditation as an input	Structurally identical in function to PIC/S-member/WHO-prequalification GMP certification gating, and the Decree-Law explicitly accepts a country-of-origin or EDE-accredited-reference-body GMP certificate in lieu of a UAE-specific one (Art. 6(1)(f)) — this is the clearest point of direct, sourceable UAE-to-international alignment	This gating mechanism is genuinely UAE-specific law (a real, cited Decree-Law article) even though the underlying GMP technical standard it points to may in practice be a foreign or PIC/S-aligned one — don't conflate "the gate is UAE law" with "the technical content behind the gate is UAE-specific."
Technical GMP content (facility, production, QC, validation, data integrity)	Not independently re-derived here — explicitly out of scope, covered by the companion GCC-framework rubric	This is where PIC/S PE009 / EU GMP Vol. 4 / WHO TRS content would normally sit	This session found no UAE-specific, article-numbered, publicly available English text at this level of granularity. Any Regscribe scoring at this depth for a UAE document should explicitly borrow the EU GMP Vol. 4 rubric's rows, flagged as "PIC/S/EU-generic, not confirmed UAE text" per this rubric's legend, rather than presenting UAE-specific citations that don't exist.
Inspection powers, incl. unannounced (Art. 159)	Not independently researched	Directly analogous to standard PIC/S/EU/FDA unannounced-inspection authority	Genuinely UAE-specific legal basis, structurally familiar in practice.
Disciplinary/criminal penalty structure (Arts. 160, 164-168)	Not independently researched	No direct PIC/S analogue (PIC/S itself doesn't set penalties; member-state law does) — most comparable to how EU member states and the US set their own penalty statutes alongside EU-GMP/CGMP technical rules	Genuinely UAE-specific.
PIC/S membership	N/A	UAE/EDE is a pre-accession applicant (application received 5 March 2026, Rapporteur appointed 15 July 2026) — not a member	Do not describe UAE as "PIC/S-aligned" in a way that implies membership or a completed benchmarking exercise.

Gaps / follow-ups before this goes into production scoring

The single largest gap: the actual technical GMP standard the Decree-Law delegates to (Art. 127 — "quality management standards and good manufacturing practices controls issued and approved by the EDE") could not be located or confirmed as published this session. Without it, this rubric can verify UAE manufacturing-licensing procedure (certificates, terms, renewal, suspension/cancellation triggers, penalties) with high confidence, but cannot verify UAE-specific technical GMP content (facility qualification, batch documentation, validation lifecycle, deviation/CAPA mechanics, annex-level detail for sterile/biological products) the way the companion EU GMP and Japan GMP rubrics can. Recommend a dedicated follow-up session that searches ede.gov.ae directly (not attempted this session beyond its legislations-listing page) for a published GMP technical guideline, and checks whether the "Executive Regulations" of the 2024 Decree-Law have been issued since the January 2025 secondary-source snapshot that described them as "pending."
mohap.gov.ae could not be fetched at all this session — every attempt (GMP Guide 2000 and 2002 pages, the MOHAP/EDE transfer announcement, a product-withdrawal enforcement notice) failed with ECONNRESET or timeout. This blocked verification of: the historical MOHAP GMP Guides' actual content/structure/currency; the precise wording and scope of the 29 December 2025 service-transfer announcement (relied on here only via consistent secondary reporting); and the specific enforcement notice found in search results. Recommend a follow-up with a different fetch approach (e.g., a cached/archived copy, or manual retrieval) given this project's established pattern of some government sites blocking automated fetches.
DHA/DHCC's precise current operational relationship with EDE for Dubai-based manufacturers specifically was not independently verified against a DHA primary document. This rubric's claim that DHA operates a "parallel, not sequential" facility-licensing/healthcare-regulation track (rather than a competing manufacturing-GMP-certification track) rests on secondary legal commentary, cross-checked against the Decree-Law's own Art. 2(4) free-zone-inclusion language and its "Competent Health Authority" definition — internally consistent, but not confirmed via a DHA-issued document this session. If Regscribe gains a Dubai-based manufacturer customer, recommend a targeted follow-up directly against dha.gov.ae.
No verified named UAE GMP-manufacturing-inspection enforcement case exists in this rubric. Unlike the companion Japan GMP rubric (Kobayashi Kako, Nichi-Iko) or the US GLP rubric (IBT, Craven Labs), every failure-pattern cell above is a structural reading of the primary Decree-Law text, not a named precedent. This is a genuine reflection of UAE pharmaceutical-enforcement transparency (or this session's search limitations) — recommend a follow-up once a working, unrestricted WebSearch session is available, targeting Arabic-language MOHAP/EDE enforcement-notice archives specifically, since English-language coverage appears thin.
PIC/S accession is at the earliest possible stage (Rapporteur just appointed, 15 July 2026) — this rubric's PIC/S-status framing should be re-checked periodically; UAE/EDE accession is a multi-year process typically, and the current "applicant" framing will need updating as the process progresses. Recommend flagging this row for periodic review rather than treating it as static like most of the rest of this rubric.
The GCC-wide harmonisation content (GCC-DR centralised registration, GCC Health Council) was deliberately not re-derived here per this task's brief — a separate, concurrently-researched GCC-unified-framework rubric is the intended home for that content. If that companion rubric is completed, this rubric's "Cross-reference" table above should be revisited to ensure the two documents describe the GCC layer consistently rather than drifting apart.
The registry label itself (ae-mohap-rubric.md / "MOHAP" in lib/rubrics.ts) is now arguably a misnomer given EDE's primary role — flagged prominently at the top of this document. Recommend Khando's explicit decision on whether to rename the label (e.g., "UAE MOHAP/EDE (Federal Decree-Law No. 38/2024)") before this goes into the public knowledge-base listing, since a pharma/biotech customer searching for "UAE GMP" may reasonably expect to see EDE named, not only MOHAP.

UAE Drug GMP (Emirates Drug Establishment)